24-Jul-2015 - TxCell SA

TxCell raises approx. EUR 8 million through a private placement of 10 percent of its common shares

TxCell SA announced the successful completion of a private placement of a total amount of approximately EUR 8 million.

“We are extremely pleased to welcome on board new, mostly international, institutional investors, as shareholders. Whilst TxCell operates in a mainstream technology, cellular immunotherapy, we have a radically different approach compared to other industry players,” said Stéphane Boissel, CEO of TxCell. “TxCell has developed the only platform dedicated to regulatory T cells. This is a cell population that has been described as having a significant potential to treat both auto-immunity and inflammatory conditions. The industry segment is very large with more than 80 different diseases and several billion dollars in revenue for the pharma and biotech industries. This placement should certainly help us to accelerate the development of TxCell.”

“Proceeds of the placement will be used by TxCell to finance the ongoing developments in our leading two products. We will also invest more in new products or programs, such as the development of our second platform based on engineered regulatory T cells - CAR Treg,” said Raphael Flipo, CFO of TxCell. “Manufacturing operations, specifically through agreements with CMOs (Contract Manufacturing Organizations) to accelerate recruitment in the ongoing studies, will also be an important investment area in the immediate future.”

Stéphane Boissel, CEO of TxCell, subscribed 20,000 new shares, representing approximately 1.71 percent of the private placement.

Facts, background information, dossiers
  • TxCell
  • private placements
More about TxCell
  • News

    Sangamo completes acquisition of TxCell

    Sangamo Therapeutics, Inc. announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market. “The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development,” said Sandy Macrae, ... more

    Sangamo Therapeutics to acquire TxCell

    Sangamo Therapeutics and TxCell announced that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the contemplated acquisition of a majority stake of TxCell, file a simplified cash tender offer for the purchase of all t ... more

    TxCell receives Fast Track Designation from FDA for Ovasave

    TxCell SA announced  that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to TxCell’s lead product Ovasave(R) for the treatment of moderate to severe Crohn’s disease. Ovasave already has an active IND (Investigational New Drug) with the FDA. The FDA F ... more